Articles: burns.
-
Multicenter Study
Measuring health status among survivors of burn injury: revisions of the Burn Specific Health Scale.
This study examined the reliability of a revised version of the Burn Specific Health Scale (BSHS). Two hundred fifty-four former patients recruited from eight burn centers in the southeastern United States participated in the study. Data were collected via chart review and mailed questionnaire. ⋯ Each subscale exhibited a high level of reliability (Cronbach's alpha ranged from 0.82 to 0.94). Each subscale also correlated in a predictable manner with measures used for validation. The revised measure should improve the ability of both researchers and clinicians to assess the impact of non-fatal burn injury accurately and comprehensively.
-
J Burn Care Rehabil · Jan 1992
Multicenter Study Clinical TrialAddendum: multicenter experience with cultured epidermal autograft for treatment of burns.
Since 1989 BioSurface Technology, Inc. (Cambridge, Mass.) has provided over 37,000 cultured epidermal autografts (CEAs) for more than 240 patients in 79 different burn centers in the United States and Europe. The average burn treated with BioSurface's CEA has been 70% total body surface area, half of that being full-thickness. Data, verified for 104 patients, indicate an average final "take" of about 60%, with half of all patients achieving a final take greater than or equal to 70% and 22% with final take greater than or equal to 90%. ⋯ Early excision followed by temporary coverage with homograft, which is allowed to engraft, was found to be associated with a low infection rate and a higher rate of CEA take. When engrafted homograft was only partially excised, leaving a layer of "allodermis" as the graft bed for CEA, take averaged 90% among 14 patients. Thus, our analysis of the extensive experience of many burn centers now permits more specific and helpful recommendations on standards of care to maximize efficacy of CEA.
-
Multicenter Study Clinical Trial
Multicentre experience in the treatment of burns with autologous and allogenic cultured epithelium, fresh or preserved in a frozen state.
This report describes the clinical results obtained from a multicentre experience of the use of autologous and allogenic cultured human epidermal cells in the treatment of partial and full skin thickness burns. A laboratory has been organized to supply cultured epithelium to Burns Units in different cities. ⋯ Graftable cultured epithelium can be frozen and remain viable if stored in a skin bank. Such grafts were used successfully to treat patients with partial and full skin thickness wounds.
-
Multicenter Study Clinical Trial
Results of a multicenter outpatient burn study on the safety and efficacy of Dimac-SSD, a new delivery system for silver sulfadiazine.
Dimac with silver sulfadiazine (Dimac-SSD), a new silver sulfadiazine delivery system, was evaluated prospectively in a multicenter study for the treatment of outpatient burn injuries. The goal of this study was to evaluate the effect of Dimac-SSD on the microbiology of the burn wounds and to quantitate its clinical safety and efficacy. A total of 197 patients were evaluated. ⋯ Only four (2%) patients developed clinical infections; thus the Dimac-SSD appeared to have good antimicrobial effectiveness. This dressing was not associated with any organ system or metabolic side-effects and patient discomfort during application and removal was minimal. Thus this new delivery system for silver sulfadiazine was associated with excellent wound healing, a low incidence of wound infections, reduced frequency for dressing changes, and excellent patient compliance.